Leerink Partners analyst Geoff Porges maintained a Hold rating on Acceleron Pharma (NASDAQ:XLRN) on Thursday, setting a price target of $180, which is approximately 3.82% above the present share price of $173.38.
Porges expects Acceleron Pharma to post earnings per share (EPS) of -$1.05 for the fourth quarter of 2021.
The current consensus among 9 TipRanks analysts is for a Hold rating of shares in Acceleron Pharma, with an average price target of $179.88.
The analysts price targets range from a high of $180 to a low of $179.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $27.94 million and a net profit of -$63.66 million. The company's market cap is $10.6 billion.
According to TipRanks.com, Leerink Partners analyst Geoff Porges is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 3.0% and a 49.79% success rate.
Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.